Quintrio
Home

Stock overview

Pulsenmore Ltd. Ordinary Shares

PLSM

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.22 – $1.43
Volume 18,843
Market cap $9M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for PLSM.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for PLSM.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

These Small Caps are Turning Up the Heat

Several small-cap companies announced significant developments this week: Twin Vee PowerCats is merging with USFM Corporation and pivoting toward critical minerals exploration in Greenland; Xeriant's NEXBOARD construction material passed independent testing; Pulsenmore received $1 million in government-backed AI funding for healthcare applications; and LogProstyle announced a new quarterly dividend.

Benzinga

Pulsenmore Announces Full Year 2025 Financial Results and Webcast

Pulsenmore Ltd. (NASDAQ: PLSM) reported full year 2025 revenues of $12.5 million, a 374% increase from 2024, though $9.6 million came from a one-time GE settlement. The company reduced net losses to $5 million from $10 million year-over-year and holds $21.7 million in liquid assets. The company achieved FDA clearance for remote prenatal ultrasound in the U.S. and CE certification in Europe, positioning itself for commercial expansion in the prenatal diagnostics market.

Benzinga

Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center

Pulsenmore Ltd. (NASDAQ: PLSM) announced its first commercial engagement in the United States with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles. Under the agreement, CFFM will purchase Pulsenmore's home ultrasound services for remote pregnancy monitoring. This milestone follows the company's recent FDA clearance for its home pregnancy ultrasound product and represents a significant step in implementing its U.S. market strategy.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.